News

Home/News
News 2017-06-21T13:15:59+00:00
August 1, 2017
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
August 1, 2017
Threshold Pharmaceuticals Announces Results of Annual Meeting of Stockholders
MENLO PARK, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (THLD) announced today that its stockholders approved all of the proposals presented at ...
August 1, 2017
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
IRVING, Texas, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of ...
August 1, 2017
VALNEVA Announces Expansion of its Management Board - Strengthening Senior Management for Future Growth
Lyon (France), August 1, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, ...
August 1, 2017
20 Executives Selected for Women In Bio’s Second Boardroom Ready Class: Preparing Women in Life Sciences for Boards of Directors Roles
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Gender equality momentum continues, as an additional 20 accomplished female life sciences executives will comprise the second cohort ...
July 31, 2017
Transgene: First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
Transgene (TNG.PA), a company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated in a Phase 1/2 clinical trial evaluating ...
July 31, 2017
Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma
Onxeo S.A. (ONXEO.PA) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs ...
July 31, 2017
Kitov Submits New Drug Application to FDA for KIT-302
TEL AVIV, Israel, July 31, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted ...
July 31, 2017
ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods
RAMSEY, N.J. and BOCA RATON, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin  company ...
July 31, 2017
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results
HOPKINTON, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
July 31, 2017
Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that the Company will release its second quarter 2017 financial results and ...
July 31, 2017
Threshold Pharmaceuticals Reports Second Quarter Financial Results
MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (THLD) today reported financial results for the second quarter ended June 30, 2017 ...
July 31, 2017
Zealand reports royalty revenue for the second quarter of 2017
Copenhagen, July 31, 2017 - Zealand Pharma ("Zealand") reports Q2 2017 royalty revenue from Sanofi`s sales of Lyxumia®/Adlyxin(TM) (lixisenatide) of DKK 5.2 million and from ...
July 31, 2017
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
BOTHELL, Wash., July 31, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage ...
July 31, 2017
BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update
RALEIGH, N.C., July 31, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, announced ...
July 31, 2017
Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment ...
July 31, 2017
iCAD to Report Second Quarter 2017 Financial Results on Tuesday, August 8
NASHUA, N.H., July 31, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...
July 31, 2017
Ohr Pharmaceutical to Announce Fiscal Third Quarter 2017 Results on August 8
NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that ...
July 31, 2017
Altimmune to Announce Second Quarter 2017 Financial Results on August 10
GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the ...
July 31, 2017
Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the underwriters of its previously announced underwritten public offering of 6,250,000 shares of ...
Page 18 of 33